Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug
by
Samareh Azeredo da Silveira 1,* and Andrew F. Shorr 2
Samareh Azeredo da Silveira 1,* and Andrew F. Shorr 2
1
Combioxin SA, 8 rue de la Rôtisserie, 1204 Geneva, Switzerland
2
Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2020, 9(2), 94; https://doi.org/10.3390/antibiotics9020094
Received: 23 January 2020 / Revised: 16 February 2020 / Accepted: 17 February 2020 / Published: 21 February 2020
(This article belongs to the Special Issue Nontraditional Antibiotics—Challenges and Triumphs)
Background: Poor outcomes in severe and resistant infections, together with the economic struggles of companies active in the field of anti-infective development, call for new solutions and front runners with novel approaches. Among “non-traditional” approaches, blocking virulence could be a game changer. Objectives: This review offers a perspective on parameters that have determined the development path of CAL02, a novel anti-virulence agent, with a view to steering clear of the obstacles and limitations that impede market sustainability for new anti-infective drugs. Conclusions and implications of key findings: This case study highlights four pillars that may support the development of other non-traditional drugs and, concurrently, provide a new model that could reshape the field. Therapeutic triggers, study designs, and economic parameters are discussed.
View Full-Text
Keywords:
severe infections; pneumonia; virulence; broad-spectrum; nontraditional; toxins; endpoint
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Azeredo da Silveira, S.; Shorr, A.F. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics 2020, 9, 94.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
